TABLE 1.
Descriptive characteristics of included children by study outcome
| Cohort (n = 6726) | Free of CDA (n = 5419, 80.6%) | CDA (n = 1296, 19.3%) | Celiac disease (n = 529, 7.9%) | |
|---|---|---|---|---|
| Country, n (%) | ||||
| United States | 2697 (40.1) | 2214 (40.9) | 481 (37.1) | 178 (33.6) |
| Sweden | 2094 (31.1) | 1601 (29.6) | 484 (37.3) | 242 (45.7) |
| Finland | 1529 (22.7) | 1261 (23.3) | 265 (20.4) | 89 (16.8) |
| Germany | 406 (6.0) | 339 (6.3) | 66 (5.1) | 20 (3.8) |
| Female, n (%) | 3291 (48.9) | 2549 (47.0) | 735 (56.7) | 319 (60.3) |
| HLA genotype, n (%) | ||||
| DQ2/DQ21 | 1397 (20.8) | 864 (15.9) | 526 (40.6) | 262 (49.5) |
| DQ2/DQ82 | 2637 (39.2) | 2130 (39.3) | 504 (38.9) | 180 (34.0) |
| Other HLA antigen genotypes3 | 2692 (40.0) | 2425 (44.7) | 266 (20.5) | 87 (16.4) |
| First-degree relative with celiac disease, n (%) | 329 (4.9) | 173 (3.2) | 155 (12.0) | 94 (17.8) |
CDA, celiac disease autoimmunity; HLA, human leucocyte antigen.
Percentages may not add to 100% due to rounding.
1
Including genotype DR3∗0501/0201∗DR3∗0501/0201
2
Including genotype DR4∗030X/0302∗DR3∗0501/0201
3
Including genotypes DR4∗030X/0302∗DR4∗030X/0302, DR4∗030X/0302∗DR4∗030X/020X, DR4∗030X/0302∗DR8∗0401/0402, DR4∗030X/0302∗DR1∗0101/0501, DR4∗030X/0302∗DR13∗0102/0604, DR4∗030X/0302∗DR4∗030X/0304, DR4∗030X/0302∗DR9∗030X/0303, DR3∗0501/0201∗DR9∗030X/0303.